clinical trial · NCT05904470
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Chronic Hepatitis C VirusHepatitis C, ChronicHepatitis CHepatic CirrhosisHCVBemnifosbuvirRuzasvir
brief summary
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
started
May 30, 2023
primary completion
Dec 9, 2024
completion
Jan 28, 2025
last updated
Oct 21, 2025
official title
A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol